Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Myelodysplastic Syndromes 382Leukemia, Myeloid, Acute 356Precursor Cell Lymphoblastic Leukemia-Lymphoma 184Leukemia 149Leukemia, Myelogenous, Chronic, BCR-ABL Positive 147Leukemia, Myelomonocytic, Chronic 128Myeloproliferative Disorders 114Leukemia, Lymphocytic, Chronic, B-Cell 100Primary Myelofibrosis 99Multiple Myeloma 89Lymphoma, Non-Hodgkin 89Hodgkin Disease 76Blast Crisis 68Lymphoma 62Leukemia, Myeloid, Chronic-Phase 58Lymphoma, Large B-Cell, Diffuse 53Lymphoma, Mantle-Cell 52Lymphoma, Follicular 52Burkitt Lymphoma 52Hematologic Neoplasms 51Leukemia, Myeloid, Accelerated Phase 50Congenital Abnormalities 47Polycythemia Vera 45Lymphoma, B-Cell, Marginal Zone 44Thrombocythemia, Essential 43Lymphoma, Large-Cell, Immunoblastic 43Anemia, Refractory, with Excess of Blasts 42Myelodysplastic-Myeloproliferative Diseases 41Neoplasms, Plasma Cell 40Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 40

Interventions

ivosidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × IDH1 Mutation Myeloid Neoplasms × Myeloid × Clear all
NCT03564821 2025-11-04

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Massachusetts General Hospital

Phase 1 Completed
18 enrolled
Myeloid

IDH1 Mutation Myeloid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡